Company intelligence / Profile preview

Anno Bio

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

AnnoBio is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on the development of mRNA-based vaccines and therapeutics. The company utilizes a proprietary lipid nanoparticle (LNP) delivery system and mRNA synthesis platform to address infectious diseases and various cancers. Its lead candidate, AB-001, is an mRNA vaccine for COVID-19 that has entered Phase 2 clinical evaluation. AnnoBio's broader pipeline includes programs for seasonal influenza and personalized cancer vaccines, positioning the firm as a key player in the emerging Chinese mRNA landscape. The company is led by a management team with deep expertise in RNA biology and drug delivery technologies.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyBiologicVaccine
Industry: Biotech

Beyond the preview

Go deeper on Anno Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anno Bio.

Explore the full profile